How to read a provider, a menu, and a profile. 135 articles, newest first.
Many people can produce milk after breast augmentation, lift, or reduction, but no consultation can promise a full supply. The operation's effect on glandular tissue, ducts, nerves, nipple–areola blood supply, and implant position matters, as do pregnancy, milk removal, and postpartum support.
Cannabis is not one perioperative exposure. THC, CBD, prescription cannabinoids, smoked or vaped products, edibles, oils, and topicals differ. Frequency, last use, intoxication, airway effects, other medicines, and withdrawal can change an anesthesia plan; the actual team should set instructions.
No topical finasteride product is FDA-approved in the United States. Compounded sprays, gels, and combination products can create systemic and transfer exposure, but FDA adverse-event reports cannot establish incidence. Verify the prescription, ingredients, concentration, route, pharmacy, and risk instructions.
A postoperative garment may provide support or affect comfort and swelling, but current evidence does not establish one faja design or wear schedule as necessary for every liposuction or tummy-tuck patient. The operation, fit, pressure, symptoms, and surgeon's written plan matter more than the garment's stage number.
Local anesthesia numbs tissue; sedation changes consciousness along a minimal-to-deep continuum; general anesthesia produces unresponsiveness and usually requires airway support. “Awake,” “twilight,” and “MAC” do not fully specify the intended depth, personnel, monitoring, or rescue plan.
BMI can correlate with some procedure-specific complications, but it is a screening proxy—not a universal candidacy rule or a biological cliff. A quoted cutoff may belong to a surgeon, anesthesia group, facility, payer, or study, and each means something different.
A nodule that appears weeks, months, or years after filler needs a product-specific differential, not a photo diagnosis or automatic dissolving. The workup should identify the exact material and placement, describe the nodule's clinical pattern, test defined possibilities when indicated, and assign follow-up ownership.
FDA approved specified boxed-warning changes for an initial group of menopausal hormone therapy products in February 2026. It did not erase every warning from every product, approve compounded hormones, or make all routes and formulations interchangeable. Read the current product-specific label.
Animal-derived or desiccated thyroid products marketed in the United States are not FDA-approved. FDA's current transition and enforcement approach does not convert them into approved drugs, prove every prescription unlawful, or tell an individual to stop abruptly; exact product and prescriber records remain essential.
A mommy makeover is not one standardized operation. Combining breast, abdominal, and liposuction procedures may reduce separate recovery episodes, while staging can shorten each operation and simplify recovery. The decision depends on the exact procedures, risk profile, facility, anesthesia, aftercare, and goals.
Cigarettes, nicotine vapes, pouches, lozenges, gum, patches, and other products are not interchangeable exposures, but hidden noncombustible nicotine can undermine surgical planning. Reconcile source, use pattern, smoke or aerosol exposure, cessation support, testing, and procedure-specific timing with the care team.
A preoperative workup is not a universal bundle of labs, ECG, pregnancy testing, and cardiac studies. The anesthesia and surgical teams select information that could change a defined plan, then own the review and follow-up of results.
A prior tummy tuck does not prevent pregnancy, and limited published evidence does not make pregnancy afterward automatically contraindicated. Pregnancy can still stretch repaired tissues, change scars or contour, and create operation-specific obstetric and anesthesia questions, so the operative record matters.
FDA's Pharmacy Compounding Advisory Committee considered several peptide bulk substances in July 2026, but a committee discussion or vote is advisory. It is not drug approval, a final FDA order, automatic addition to the 503A bulks list, or evidence that a clinic's product is safe, effective, or lawfully compounded.
Breast implant illness is a patient-used term for systemic symptoms reported after implantation, not a single formally defined diagnosis. A useful evaluation preserves the symptom timeline, implant record, competing explanations, and the limits of current evidence before any operation is treated as a test or cure.
“Cosmeceutical” has no meaning under federal law, and “medical grade” is not an FDA approval category. Classify the exact offering by intended use and, for a possible device, how its primary purpose is achieved; then verify labeling, status, evidence, and claims separately.
BIA-ALCL is a lymphoma usually found in fluid or capsule around an implant; reported breast-implant capsule SCC is an epithelial cancer in capsule tissue. Neither is ordinary breast cancer or diagnosed by routine silent-rupture imaging. A symptom-triggered workup needs implant, imaging, fluid, and pathology records.
Do not stop or change an anticoagulant, antiplatelet drug, NSAID, vitamin, herb, or supplement from a generic cosmetic-clinic list. The prescriber and procedural team must reconcile the exact product, indication, dose, timing, procedure bleeding risk, clot risk, anesthesia, and restart owner in writing.
There is no single stop interval for every GLP-1 medicine or cosmetic procedure. The decision depends on the exact drug and formulation, dose phase, gastrointestinal symptoms, other delayed-emptying risks, and whether the plan uses general anesthesia, deep sedation, lighter sedation, or local treatment only.
Pregnancy and contraception instructions are product-, formulation-, and indication-specific. Tirzepatide labeling addresses oral-hormonal-contraceptive effectiveness after starting and dose escalation; Wegovy's planned-pregnancy and recognized-pregnancy instructions vary by indication.
A consumer stool microbiome report can describe what its laboratory and algorithm detected, but it does not automatically diagnose dysbiosis or validate a personalized diet or supplement plan. Analytical reproducibility, reference claims, clinical validity, and recommendation utility are separate links.
Current isotretinoin labeling still gives a six-month warning for waxing and skin resurfacing, while later reviews find that evidence does not support one delay for every procedure. Reconcile the exact product label, procedure, depth, evidence, and responsible clinicians.
A cosmetic label such as “mole” or “skin tag” is not a diagnosis. Before laser, plasma, cautery, freezing, shaving, or snipping, establish who identified the lesion, whether tissue should be preserved for pathology, and who owns the result and follow-up.
A numbing cream is a drug exposure, not a neutral comfort add-on. Product status, active ingredients, concentration, grams applied, body surface area, skin condition, exposure time, occlusion, other local anesthetics, and supervision all affect what the label or prescription actually supports.
Travel changes cosmetic surgery from one episode into a chain across surgeon, facility, lodging, transportation, flight timing, wound and medication records, local follow-up, and emergency care. A low package price or short return date is not a continuity plan; assign who owns each phase before payment.
High-frequency ultrasound can map existing filler and anatomy, guide selected injections, or localize material during complication evaluation. It is not a universal clearance test and cannot guarantee vessel avoidance; value depends on a trained operator answering a defined question and documenting the changed plan.
MRI without contrast and high-resolution ultrasound can evaluate silicone implant integrity, but that surveillance does not replace age- and risk-appropriate breast-cancer screening. Start with implant type, symptoms, surgery date, and the imaging question.
A licensed injector and a familiar-looking carton do not independently prove product authenticity. Verify the exact prescription product, U.S. labeling, sealed vial, lot record, authorized supply chain, and clinician before an injection.
A filler consultation should identify the exact product and injection sites, then show how the practice would recognize and route a possible vascular event. Product reversibility, anatomy, on-site capabilities, escalation contacts, and staff coverage all matter.
A surgeon may include manual lymphatic drainage in an individualized recovery plan, but direct evidence does not establish a universal massage schedule or isolate its benefit after cosmetic liposuction. It cannot diagnose a fluid collection or replace surgical follow-up.
A new needle is only one control. Safe injection practice also requires a new sterile syringe, aseptic preparation, correct single- or multi-dose vial handling, clean medication areas, immediate sharps disposal, and a traceable product record.
HIPAA applies only to covered entities and business associates, but a non-HIPAA business does not have a free pass to misuse health data. Treatment consent, clinical photography, marketing authorization, app sharing, and testimonial permission are separate decisions.
A consumer tracker estimates sleep from limited sensors and is not a diagnostic study. A home sleep apnea test measures selected breathing signals for an ordered apnea evaluation in appropriate adults. Polysomnography records sleep stages, breathing, oxygen, heart rhythm, and movements under supervision.
Before a stem-cell injection or IV, match the exact product and use to one path: FDA approval/licensure; a product-specific basis meeting every section 361 criterion; or a legitimate investigation under an IND in effect. A clinic's 361 claim, registration, or screenshot is not FDA agreement or marketing approval.
Before-and-after images, testimonials, and reviews can reveal questions to ask, but they are also advertising claims. Read them for identity, comparability, typicality, disclosures, and missing context before treating them as evidence of a likely result.
Off-label means an FDA-approved drug or cleared or approved device is being used outside its labeled conditions. It is different from using an unapproved product, and it does not by itself prove that a use is appropriate, unsafe, or supported by strong evidence.
A telehealth weight-loss brand can connect several separate parties: platform, prescriber, lab, pharmacy, and compounder. Verify each party, the exact dispensed drug, its FDA status, and the full continuity plan before comparing a monthly offer.
FDA's 2026 requested label updates removed prior age-related limitation language and revised prostate information, but approved testosterone products still have defined indications. Diagnosis, product, route, monitoring, fertility, and blood pressure require precision.
Turn a long service list into a useful comparison: find the exact service, open its source, identify the clinician involved, and look for dated credential checks.
